Cadila Healthcare gains on USFDA nod for anti-diabetic drug

The company has received final approval from the USFDA for Glyburide and Metformin Hcl tablets USP

Bs_logoCadila Healthcare gains on USFDA nod for anti-diabetic drug
SI Reporter Mumbai
Last Updated : Mar 01 2016 | 2:05 PM IST
Shares of Cadila Healthcare were up over 2% at Rs 322 after the company said that it has received final approval from the USFDA for Glyburide and Metformin Hcl tablets USP from its formulation manufacturing facility at Baddi.

The final approval from the USFDA is for Glyburide and Metformin Hcl tablets USP in strengths of 1.25/250, 2.5/500 and 5/500 mg, the company said in a release.

The drug falls in the anti-diabetics segment and the group's formulations manufacturing site at Baddi will be producing the drug for the US market.

The stock opened at Rs 317 and touched a high of Rs 325. At 2pm, over 569,000 shares were traded on both the stock exchanges.

Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 01 2016 | 2:04 PM IST